Dialyzer Membrane Characteristics and Outcome of Patients With Type 2 Diabetes on Maintenance Hemodialysis

American Journal of Kidney Diseases

Volumn 49, Issue 2, 2007, Pages 267-275

  Krane, Vera ^a   Krieter, Detlef H ^a   Olschewski, Manfred ^a   März, Winfried ^a   Mann, Johannes F E ^a   Ritz, Eberhard ^a   Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

clinical trial; Diabetes mellitus; German Diabetes and Dialysis (4D) Study; hemodialysis; membranes; mortality

Indexed keywords

ATORVASTATIN;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS MEMBRANE; DOUBLE BLIND PROCEDURE; FEMALE; HEART DEATH; HEART INFARCTION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; RENAL DIALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846638745     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.11.026     Document Type: Article

References (31)

1. Hakim R.M., Held P.J., Stannard D.C., et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 50 (1996) 566-570
2. Jaber B.L., Lau J., Schmid C.H., Karsou S.A., Levey A.S., and Pereira B.J. Effect of biocompatibility of hemodialysis membranes on mortality in acute renal failure: A meta-analysis. Clin Nephrol 57 (2002) 274-282
3. Alonso A., Lau J., and Jaber B.L. Biocompatible hemodialysis membranes for acute renal failure. Cochrane Database Syst Rev 2 (2005) CD005283
4. Macleod A.M., Campbell M., Cody J.D., et al. Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. Cochrane Database Syst Rev 3 (2005) CD003234
5. Koda Y., Nishi S., Miyazaki S., et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52 (1997) 1096-1101
6. Locatelli F., Marcelli D., Conte F., Limido A., Malberti F., and Spotti D. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 55 (1999) 286-293
7. Port F.K., Wolfe R.A., Hulbert-Shearon T.E., et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the USRDS Dialysis Morbidity and Mortality Study. Am J Kidney Dis 37 (2001) 276-286
8. Woods H.F., and Nandakumar M. Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 15 suppl 1 (2000) S36-S42
9. Chauveau P., Nguyen H., Combe C., and French Study Group for Nutrition in Dialysis. Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 45 (2005) 565-571
10. Eknoyan G., Beck G.J., Cheung A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 (2002) 2010-2019
11. US Renal Data System: USRDS 2005 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005. Available at: http://www.usrds.org. Accessed June 28, 2006
12. Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
13. Wanner C., Krane V., Marz W., et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D Study): Demographic and baseline characteristics. Kidney Blood Press Res 27 (2004) 259-266
14. Cheung A.K., Levin N.W., Greene T., et al. Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO Study. J Am Soc Nephrol 14 (2003) 3251-3263
15. Canaud B., Bragg-Gresham J.L., Marshall M.R., et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 69 (2006) 2087-2093
16. Jirka T., Cesare S., and Di B.A. The impact of on-line haemodiafiltration (HDF) on patient survival: Results from a large network database. Nephrol Dial Transplant 20 suppl 4 (2005) S18-S19
17. Josephson M.A., Fellner S.K., and Dasgupta A. Improved lipid profiles in patients undergoing high-flux dialysis. Am J Kidney Dis 20 (1992) 361-366
18. Seres D.S., Strain G.W., Hashim S.A., Goldberg I.J., and Levin N.W. Improvement of plasma lipoprotein profiles during high flux dialysis. J Am Soc Nephrol 3 (1993) 1409-1415
19. Churchill D.N., Taylor D.W., Tomlinson C.W., Beecroft M.L., Gorman J., and Stanton E. Effect of high-flux hemodialysis on cardiac structure and function among patients with end-stage renal failure. Nephron 65 (1993) 573-577
20. Coyne D.W., Dagogo-Jack S., Klein S., Merabet E., Audrain J., and Landt M. High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients. Am J Kidney Dis 32 (1998) 1031-1035
21. Haag-Weber M., Mai B., Cohen G., and Hörl W.H. GIP and DIP: A new view of uraemic toxicity. Nephrol Dial Transplant 9 (1994) 34-37
22. Dursun E., Timur M., Dursun B., Suleymanlar G., and Ozben T. Protein oxidation in type 2 diabetic patients on hemodialysis. J Diabetes Complications 19 (2005) 142-146
23. Mera K., Anraku M., Kitamura K., et al. Oxidation and carboxy methyl lysine-modification of albumin: Possible involvement in the progression of oxidative stress in hemodialysis patients. Hypertens Res 28 (2005) 973-980
24. Weiss M.F., Erhard P., Kader-Attia F.A., et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 57 (2000) 2571-2585
25. Wanner C., Bahner U., Mattern R., Lang D., and Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 2570-2575
26. Hakim R.M. Influence of the dialysis membrane on outcome of ESRD patients. Am J Kidney Dis 32 suppl 5 (1998) S71-S75
27. Wanner C., Zimmermann J., Schwedler S., and Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 80 (2002) S99-S102
28. Honda H., Qureshi A.R., Heimburger O., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47 (2006) 139-148
29. Parker III T.F., Wingard R.L., Husni L., Ikizler T.A., Parker R.A., and Hakim R.M. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 49 (1996) 551-556
30. Ward R.A. Ultrapure dialysate. Semin Dial 17 (2004) 489-497
31. Laude-Sharp M., Caroff M., Simard L., Pusineri C., Kazatchkine M.D., and Haeffner-Cavaillon N. Induction of IL-1 during hemodialysis: Transmembrane passage of intact endotoxins (LPS). Kidney Int 38 (1990) 1089-1094